Chemical Compound Review:
Entinostat pyridin-3-ylmethyl N-[[4-[(2...
Synonyms:
SNDX-275, PubChem24433, CHEMBL27759, S1053_Selleck, SureCN148309, ...
- Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Camphausen, K., Burgan, W., Cerra, M., Oswald, K.A., Trepel, J.B., Lee, M.J., Tofilon, P.J. Cancer Res. (2004)
- Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Ryan, Q.C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J.B., Ye, J., Figg, W.D., Hwang, K., Chung, E.J., Murgo, A., Melillo, G., Elsayed, Y., Monga, M., Kalnitskiy, M., Zwiebel, J., Sausville, E.A. J. Clin. Oncol. (2005)
- MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Lee, B.I., Park, S.H., Kim, J.W., Sausville, E.A., Kim, H.T., Nakanishi, O., Trepel, J.B., Kim, S.J. Cancer Res. (2001)
- Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Wang, X.F., Qian, D.Z., Ren, M., Kato, Y., Wei, Y., Zhang, L., Fansler, Z., Clark, D., Nakanishi, O., Pili, R. Clin. Cancer Res. (2005)
- The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Simonini, M.V., Camargo, L.M., Dong, E., Maloku, E., Veldic, M., Costa, E., Guidotti, A. Proc. Natl. Acad. Sci. U.S.A. (2006)
- A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., Nakanishi, O. Proc. Natl. Acad. Sci. U.S.A. (1999)
- Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Fournel, M., Trachy-Bourget, M.C., Yan, P.T., Kalita, A., Bonfils, C., Beaulieu, C., Frechette, S., Leit, S., Abou-Khalil, E., Woo, S.H., Delorme, D., MacLeod, A.R., Besterman, J.M., Li, Z. Cancer Res. (2002)
- In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. Hahnen, E., Eyüpoglu, I.Y., Brichta, L., Haastert, K., Tränkle, C., Siebzehnrübl, F.A., Riessland, M., Hölker, I., Claus, P., Romstöck, J., Buslei, R., Wirth, B., Blümcke, I. J. Neurochem. (2006)
- Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Hölsken, A., Eyüpoglu, I.Y., Lueders, M., Tränkle, C., Dieckmann, D., Buslei, R., Hahnen, E., Blümcke, I., Siebzehnrübl, F.A. Acta Neuropathol. (2006)
- Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives. Nagaoka, Y., Maeda, T., Kawai, Y., Nakashima, D., Oikawa, T., Shimoke, K., Ikeuchi, T., Kuwajima, H., Uesato, S. European journal of medicinal chemistry. (2006)
- Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Eyüpoglu, I.Y., Hahnen, E., Tränkle, C., Savaskan, N.E., Siebzehnrübl, F.A., Buslei, R., Lemke, D., Wick, W., Fahlbusch, R., Blümcke, I. Mol. Cancer Ther. (2006)
- The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Rosato, R.R., Almenara, J.A., Grant, S. Cancer Res. (2003)
- MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C.J., Robey, R., Bates, S.E., Thiele, C.J. Cancer Res. (2002)
- Histone Deacetylase Inhibitors Induce Apoptosis with Minimal Viral Reactivation in Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus. Niedermeier, A., Talanin, N., Chung, E.J., Sells, R.E., Borris, D.L., Orenstein, J.M., Trepel, J.B., Blauvelt, A. J. Invest. Dermatol. (2006)
- Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Acharya, M.R., Karp, J.E., Sausville, E.A., Hwang, K., Ryan, Q., Gojo, I., Venitz, J., Figg, W.D., Sparreboom, A. Investigational new drugs. (2006)
- Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Chung, E.J., Lee, S., Sausville, E.A., Ryan, Q., Karp, J.E., Gojo, I., Telford, W.G., Lee, M.J., Kong, H.S., Trepel, J.B. Ann. Clin. Lab. Sci. (2005)
- Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Dai, Y., Rahmani, M., Dent, P., Grant, S. Mol. Cell. Biol. (2005)
- The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Maggio, S.C., Rosato, R.R., Kramer, L.B., Dai, Y., Rahmani, M., Paik, D.S., Czarnik, A.C., Payne, S.G., Spiegel, S., Grant, S. Cancer Res. (2004)
- Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Owa, T., Yoshino, H., Yoshimatsu, K., Nagasu, T. Current medicinal chemistry. (2001)
- Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. Moody, T.W., Nakagawa, T., Kang, Y., Jakowlew, S., Chan, D., Jensen, R.T. J. Mol. Neurosci. (2006)
- Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. Park, S.H., Lee, S.R., Kim, B.C., Cho, E.A., Patel, S.P., Kang, H.B., Sausville, E.A., Nakanishi, O., Trepel, J.B., Lee, B.I., Kim, S.J. J. Biol. Chem. (2002)